1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
AVE Science & Technology Co., Ltd. Class A

AVE Science & Technology Co., Ltd. Class A

SSSE:688067
20.99
CNY
-0.43
(-2.01%)
1.37BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.61
1.58
1.81
2.29
2.63
2.92
3.72
3.53
3.57
2.85
2.98
3.03
3.27
- -
Basic EPS, GAAP
0.39
0.34
0.48
0.54
0.49
0.53
0.99
0.59
0.53
0.26
0.32
0.34
0.43
- -
Free Cash Flow per Basic Share
0.15
-0.3
0.07
0.17
-0.46
0.45
0.74
0.69
0.45
0.12
0.27
0.28
0.57
- -
Dividend per Share
- -
- -
0.3
- -
0.2
- -
0.3
0.9
- -
0.3
0.1
0.1
0.15
0.05
Book Value per Share
2.41
2.71
2.89
3.44
3.72
4.26
4.95
4.64
7.02
6.99
7.2
7.29
7.56
7.73
Tangible Book Value per Share
2.41
2.25
2.44
2.99
3.28
3.83
4.53
4.21
6.71
6.66
6.87
6.94
7.22
7.39
Basic Weighted Avg Shares
51
50
51
51
51
51
51
51
59
69
67
67
67
67
Sales/Revenue/Turnover
82
80
92
117
134
151
190
180
211
197
200
203
220
- -
Operating Margin (%)
14.83
12.56
16.43
16.82
22.06
20.47
30.48
19.61
15.24
6.62
8.48
8.52
11.35
- -
Depreciation Expense
2
2
2
2
4
5
5
6
7
9
11
12
12
- -
Net Income, GAAP
20
17
25
28
25
27
51
30
31
18
22
23
29
- -
Effective Tax Rate (%)
7.97
10.4
10
12.39
14.24
9.63
11.6
10.31
7.77
1.24
3.69
2.93
3.58
- -
Profit Margin (%)
24.3
21.51
26.54
23.62
18.6
18.12
26.59
16.7
14.85
9.13
10.75
11.23
13.14
- -
Working Capital
66
72
62
68
46
69
85
67
296
272
238
250
325
320
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
123
138
148
175
190
217
253
237
478
475
490
496
514
525
Return on Invested Capital (%)
9.98
6.88
9.27
10.34
13.62
13.34
21.56
12.66
8.86
3.84
4.48
4.67
5.76
- -
Return on Capital (%)
17.57
13.11
17.18
17.13
13.66
13.38
21.45
12.26
8.76
3.77
4.46
4.63
5.75
- -
Return on Common Equity (%)
17.61
13.11
17.18
17.13
13.68
13.4
21.51
12.31
8.76
3.77
4.46
4.63
5.72
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
30
40
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
68
68
68
Market Capitalization
1,670
1,786
1,370

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
382
388
419
Cash, Cash Equivalents & STI
146
201
204
Accounts Receivable, Net
6
6
6
Inventories
42
48
50
Total Current Liabilities
57
85
99
Payables & Accruals
- -
- -
- -
ST Debt
- -
30
40
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.08%
21.86%
3.73%
Free Cash Flow
-23.19%
25.85%
105.39%
Net Income, GAAP
7.06%
2.73%
26.38%
Sales/Revenue/Turnover
9.61%
4.33%
8.05%
Total Cash Common Dividend
- -
- -
52.36%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
47
50
56
50
203
2025
53
56
- -
49
220
2026
53
60
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.07
0.1
0.2
-0.03
0.34
2025
0.09
0.11
- -
-0.01
0.43
2026
0.11
0.15
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.02
- -
0.1
2025
- -
- -
- -
0.05
0.15
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jian Wen Ding
Full Time Employees
510
Sector
Health technology
Industry
Medical specialties
Address
No. 26, Fuling Road Changsha HU China 410208
IPO Date
Jun 16, 2021
Website
c-ave.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
AVE Science & Technology Co Ltd (688067:SHH) develops, manufactures, markets, and services clinical testing and analysis instruments, in vitro diagnostic reagents, and medical consumables; its core products include AVE-76 series urine formed elements analyzers and related reagents, AVE-75 series automatic urine analyzers, AVE-66 series multi-function microscopy analyzers, AVE-85 series semi-automatic biochemical analyzers, AVE-55 series feces analyzers, vaginal secretions analyzers, blood morphology analyzers, POCT reagents, urine analyzer cleansers, test strips, and quality control products. Founded in 2000 and headquartered in Changsha, Hunan Province, China, the company operates a marketing network across all 31 provinces in China with over 10,000 units installed in more than 6,000 hospitals domestically, achieving nearly 40% market share for dominant products, while serving international markets in Europe, North America, South America, Asia-Pacific, Middle East, and Africa. In October 2024, AVE Science & Technology invested RMB 10 million in Luying Technology, acquiring a 9.07% stake to expand its strategic capabilities in related technologies.